Search results for "Science & Technology"

showing 10 items of 723 documents

PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation

2019

OBJECTIVE: To identify disease-causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. METHODS: We performed genome-wide sequencing, homozygosity mapping, and segregation analysis for novel disease-causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titration calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombinant protein, patient-derived fibroblasts, plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating sc…

0301 basic medicineMale[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyLOCAL TRANSLATIONMedizinmedicine.disease_causeDISEASEchemistry.chemical_compound0302 clinical medicinepolineuropathyCinètica enzimàticaGene Regulatory NetworksPyridoxal phosphateChildPyridoxal KinaseAdenosine triphosphate (ATP)Research ArticlesAged 80 and overMutationGene Regulatory NetworkPLASMAAutosomal recessive axonal polyneuropathyDisease gene identificationPyridoxal kinase3. Good healthSettore MED/26 - NEUROLOGIANeuropaties perifèriquesTreatment OutcomePolyneuropathieNeurologyChild PreschoolPyridoxal PhosphateRELIABILITYVitamin B ComplexFemaleLife Sciences & BiomedicinePolyneuropathyHumanResearch ArticleAdultAdolescentPDXKClinical NeurologyCHARCOT-MARIE-TOOTHCHARCOT-MARIE-TOOTH CMT NEUROPATHY SCORE LOCAL TRANSLATION DISEASE RELIABILITY; MECHANISMS DISCOVERY FRAMEWORK KINASE PLASMAMECHANISMS03 medical and health sciencesPolyneuropathiesAtrophy[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]KINASEmedicineHumansCMT NEUROPATHY SCOREPDXK mutationsPyridoxalDietary SupplementAgedPeripheral neuropathiesScience & Technology[SCCO.NEUR]Cognitive science/NeuroscienceEnzyme kineticsNeurosciencesFRAMEWORKmedicine.diseaseMolecular biology030104 developmental biologychemistryDISCOVERYDietary SupplementsMutationNeurosciences & NeurologyNeurology (clinical)Adenosine triphosphate030217 neurology & neurosurgeryAnnals of Neurology
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia

2016

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy with strong heritability. To further understand the genetic susceptibility for CLL and identify common loci associated with risk, we conducted a meta-analysis of four genome-wide association studies (GWAS) composed of 3,100 cases and 7,667 controls with follow-up replication in 1,958 cases and 5,530 controls. Here we report three new loci at 3p24.1 (rs9880772, EOMES, P=2.55 × 10−11), 6p25.2 (rs73718779, SERPINB6, P=1.97 × 10−8) and 3q28 (rs9815073, LPP, P=3.62 × 10−8), as well as a new independent SNP at the known 2q13 locus (rs9308731, BCL2L11, P=1.00 × 10−11) in the combined analysis. We find suggestive evidence (P<5 × 10−…

0301 basic medicineMedicin och hälsovetenskapChronic lymphocytic leukemiaGeneral Physics and AstronomyGenome-wide association studyVARIANTSMedical and Health SciencesMalalties hereditàries[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyChronicGeneticsRISKLeukemiaMultidisciplinaryBANK1VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801Bcl-2-Like Protein 11QAdaptor Proteins[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologySingle NucleotideLymphocytic3. Good healthPRIORITIZATIONMultidisciplinary SciencesLeukemiamedicine.anatomical_structureScience & Technology - Other TopicsTRANSCRIPTION FACTOR EOMESODERMINGenetic disordersEXPRESSIONSUSCEPTIBILITY LOCIScienceEuropean Continental Ancestry GroupFAS GENE-MUTATIONSLocus (genetics)BiologyPolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyCLASSIFICATIONWhite PeopleArticle03 medical and health sciencesProto-Oncogene ProteinsMD MultidisciplinarymedicineGenetic predispositionSNPHumansLeucèmia limfocítica crònicaGenetic Predisposition to DiseasePolymorphismB cellSerpinsGenetic associationAdaptor Proteins Signal TransducingScience & TechnologySignal TransducingB-CellMembrane ProteinsGeneral Chemistrymedicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyChronic lymphocytic leukemiaVDP::Medical disciplines: 700::Health sciences: 800::Community medicine Social medicine: 801Apoptosis Regulatory ProteinsT-Box Domain ProteinsFOLLICULAR LYMPHOMAGenome-Wide Association Study
researchProduct

“Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity…

2020

Simple Summary Despite the enormous advance in biomarker discovery, many potential biomarkers of drug activity are unable to satisfy the clinical need due to inadequate sensitivity and specificity. The nucleoside transporter hENT-1 has been studied as a potential biomarker to predict the effect of the widely used anticancer drug gemcitabine in pancreatic cancer. However, several studies showed controversial results regarding the predictive value of hENT-1, prompting new analyses with larger cohorts of patients and standardized methodologies. Improved insights on molecular mechanisms underlying hENT-1 expression and activity should also help in the identification of subsets of patients who a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFOLFIRINOXpancreatic cancerSettore BIO/05 - Zoologiaclinical outcomeDUCTAL ADENOCARCINOMAEquilibrative nucleoside transporter 1lcsh:RC254-282Articlehuman equilibrative nucleoside transporter 103 medical and health sciences0302 clinical medicinePancreatic cancerInternal medicinemedicine1112 Oncology and CarcinogenesisScience & Technologydrug resistanceROLESNucleoside analoguebiology1 HENT1business.industryCombination chemotherapyCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineRegimenLEVELS PREDICT RESPONSE030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSMETASTASISbiology.proteinSURVIVALBiomarker (medicine)ADJUVANT GEMCITABINEbusinessLife Sciences & BiomedicineRESISTANCEmedicine.drug
researchProduct

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

2017

We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected with NFAT-luciferase was used to study if changes in PD-L1 expression in cancer cell lines were functionally relevant. Five KRAS mutant cell lines with high PD-L1 expression (H441, H2291, H23, H2030 and A549) were exposed to GI50 inhibitor concentrations of a MEK inhibitor (trametinib) and an AKT inhibitor (AZD5363) for 3 weeks. Only 3/5 (H23, H2030 and A549) and 2/5 cell lines (H441 and H23) showed functionally significant increases in PD-L1 expression when exposed to…

0301 basic medicineOncologyCell signalingLung NeoplasmsLuminescenceImmunofluorescenceMutantCancer Treatmentlcsh:MedicineSignal transductionERK signaling cascademedicine.disease_causeJurkat cellsB7-H1 AntigenLung and Intrathoracic TumorsMajor Histocompatibility ComplexWhite Blood Cells0302 clinical medicineAnimal CellsCarcinoma Non-Small-Cell LungMedicine and Health Scienceslcsh:ScienceTrametinibMultidisciplinarymedicine.diagnostic_testT CellsChemistryPhysicsElectromagnetic RadiationMEK inhibitorSignaling cascadesOncology030220 oncology & carcinogenesisPhysical SciencesKRASCellular TypesResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyImmune CellsImmunologyResearch and Analysis MethodsImmunofluorescenceFluorescence03 medical and health sciencesCell Line TumorInternal medicineMD MultidisciplinarymedicineHumansImmunoassaysBlood Cellslcsh:RCancers and NeoplasmsBiology and Life SciencesCell BiologyCoculture TechniquesNon-Small Cell Lung Cancerrespiratory tract diseasesGenes ras030104 developmental biologyCell cultureMutationImmunologic TechniquesCancer researchClinical ImmunologyCancer biomarkerslcsh:QClinical MedicinePLoS ONE
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

2016

BACKGROUND: In transitioning from the Millennium Development Goal to the Sustainable Development Goal era, it is imperative to comprehensively assess progress toward reducing maternal mortality to identify areas of success, remaining challenges, and frame policy discussions. We aimed to quantify maternal mortality throughout the world by underlying cause and age from 1990 to 2015.METHODS: We estimated maternal mortality at the global, regional, and national levels from 1990 to 2015 for ages 10-54 years by systematically compiling and processing all available data sources from 186 of 195 countries and territories, 11 of which were analysed at the subnational level. We quantified eight underl…

0301 basic medicinePediatricsNutrition and DiseaseMILLENNIUM DEVELOPMENT GOALSSUSTAINABLE DEVELOPMENT GOALSANTENATAL CAREGlobal Health0302 clinical medicineVoeding en Ziekte11. SustainabilityGlobal healthHQHealthcare FinancingEMERGENCY OBSTETRIC CARE030212 general & internal medicineCooperative Behavior10. No inequalityReproductive healthMedicine(all)education.field_of_study030219 obstetrics & reproductive medicineMedicine (all)1. No povertyObstetrics and GynecologyPublic Health Global Health Social Medicine and EpidemiologyPrenatal CareGeneral Medicine11 Medical And Health SciencesLOW-RESOURCE SETTINGS3142 Public health care science environmental and occupational healthFamily Planning Service3. Good healthGBD 2015 Maternal Mortality CollaboratorsGovernment ProgramsMaternal MortalityReproductive HealthFamily Planning ServicesMaternal deathHEALTHLife Sciences & BiomedicineHumanCOUNTRIESmedicine.medical_specialtyPopulation610Prenatal careArticle03 medical and health sciencesMedicine General & InternalSDG 3 - Good Health and Well-beingCASH TRANSFER PROGRAMEnvironmental healthGeneral & Internal Medicineparasitic diseasesmedicineLife ScienceQUALITYHumansGlobal Burden of Disease StudyeducationVLAGScience & TechnologyMedical Assistancebusiness.industryKlinisk medicinParturitionObstetric transitionmedicine.diseaseQPInfant mortalityFolkhälsovetenskap global hälsa socialmedicin och epidemiologiStandardized mortality ratio030104 developmental biologyRISK-FACTORSRGClinical MedicinebusinessRA
researchProduct

Femtosecond structural dynamics drives the trans/cis isomerization in photoactive yellow protein

2016

Many biological processes depend on detecting and responding to light. The response is often mediated by a structural change in a protein that begins when absorption of a photon causes isomerization of a chromophore bound to the protein. Pande et al. used x-ray pulses emitted by a free electron laser source to conduct time-resolved serial femtosecond crystallography in the time range of 100 fs to 3 ms. This allowed for the real-time tracking of the trans-cis isomerization of the chromophore in photoactive yellow protein and the associated structural changes in the protein.Science, this issue p. 725A variety of organisms have evolved mechanisms to detect and respond to light, in which the re…

0301 basic medicinePhotoreceptorsTime FactorsPhotoisomerizationLightProtein ConformationPhotochemistryPhotoreceptors MicrobialMYOGLOBINProtein structureMicrobialX-RAY-DIFFRACTIONPHOTOISOMERIZATIONMOTIONSchromophoresta116MultidisciplinarySPECTROSCOPYCrystallographyChemistryPhotochemical ProcessesTime resolved crystallographyTIMEMultidisciplinary SciencesPicosecondFemtosecondphotoactive proteinsScience & Technology - Other Topicsddc:500IsomerizationStereochemistryGeneral Science & TechnologyConjugated systemArticle03 medical and health sciencesBacterial ProteinsIsomerismEXCITATIONx-ray crystallographyPhotonsScience & TechnologyPHOTOCYCLEta114CHROMOPHOREta1182PATHWAYSChromophore030104 developmental biologyfree-electron laserssense organstrans-cis isomerization
researchProduct

DNA methylation links prenatal smoking exposure to later life health outcomes in offspring

2019

Background Maternal smoking during pregnancy is associated with adverse offspring health outcomes across their life course. We hypothesize that DNA methylation is a potential mediator of this relationship. Methods We examined the association of prenatal maternal smoking with offspring blood DNA methylation in 2821 individuals (age 16 to 48 years) from five prospective birth cohort studies and perform Mendelian randomization and mediation analyses to assess whether methylation markers have causal effects on disease outcomes in the offspring. Results We identify 69 differentially methylated CpGs in 36 genomic regions (P value < 1 × 10−7) associated with exposure to maternal smoking in adolesc…

0301 basic medicinePhysiologyraskausDiseaseBioinformaticsEpigenesis Genetic/dk/atira/pure/core/keywords/icepCohort Studies0302 clinical medicinePregnancyGTP-Binding Protein gamma SubunitsEpidemiologySCHIZOPHRENIADiseaseLongitudinal StudiesProspective StudieskohorttitutkimusGenetics (clinical)Maternal smokingGenetics & HeredityRISK0303 health sciencesDNA methylationSmokingWIDEMethylationASSOCIATIONMiddle AgedDNA-metylaatio3. Good healthCausalityPREGNANCYOncologyMaternal ExposureSchizophreniaPrenatal Exposure Delayed Effects030220 oncology & carcinogenesisDNA methylationkausaliteettilifecourseLife course approachFemaleICEPLife Sciences & BiomedicineAdultTOBACCO-SMOKEMediation (statistics)medicine.medical_specialtyAdolescentOffspringBirth weightPersistenceYoung Adult03 medical and health sciencestupakointiterveysvaikutuksetMendelian randomizationGeneticsmedicineHumansMolecular BiologyMETAANALYSIS030304 developmental biologyPregnancyScience & TechnologyIDENTIFICATIONbusiness.industryMATERNAL CIGARETTE-SMOKINGResearchMediationLife courseMendelian Randomization Analysismedicine.diseaseBIRTH-WEIGHT030104 developmental biologyCpG Islandsbusiness030217 neurology & neurosurgeryGenome-Wide Association StudyDevelopmental Biology
researchProduct

Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study

2018

This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary anti…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaPatients4Concordance030106 microbiologyRespiratory Systemlcsh:MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioGUIDELINESPneumònia adquirida a la comunitatSputum cultureSerology03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicinemedicineMANAGEMENTBlood culture030212 general & internal medicinePOPULATIONpneumonia Methicillin-resistant Staphylococcus aureus PneumoniaScience & Technologymedicine.diagnostic_testbusiness.industryMORTALITYlcsh:RMicrobiologia mèdicaOriginal ArticlesGuidelinePneumoniaMedical microbiologymedicine.diseaseMicrobiologicalETIOLOGYPneumoniaDiagnostic testingREQUIRING HOSPITALIZATIONbusinessLife Sciences & BiomedicineCohort studyERJ Open Research
researchProduct